Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;238(6):1553-1561.
doi: 10.1007/s00213-021-05786-y. Epub 2021 Feb 25.

Roles of sedative-hypnotics in patients with recurrent major depressive disorder: a nationwide population-based 14-year follow-up study in Taiwan

Affiliations

Roles of sedative-hypnotics in patients with recurrent major depressive disorder: a nationwide population-based 14-year follow-up study in Taiwan

Kuo-Hsuan Chung et al. Psychopharmacology (Berl). 2021 Jun.

Abstract

Background: The use of sedatives or hypnotics and the recurrence of depression have not been adequately explored. This study investigated the roles of sedative-hypnotics in patients with major depressive disorder (MDD). Various characteristics of sedative-hypnotic use were tested as risk factors for recurrence.

Methods: Clinical records of 15,510 patients with major depressive disorder who prescribed selective serotonin reuptake inhibitors (SSR) during 1997-2009 were collected from the National Health Insurance Research Database (NHIRD). Cox proportional hazard regression models were used to analyze factors related to depression recurrence.

Results: The risk of MDD recurrence was lower for patients using SED/HYP with an indication of both anxiolytics and hypnotics (AHR = 0.66; 95% CI = 0.59-0.72) than for those using SED/HYP with an indication of anxiolytics only. AHR was slightly greater in current users than in recent users (AHR = 0.77; 95% CI = 0.72-0.83) and past users (AHR = 0.70; 95% CI = 0.67-0.74). There was a higher AHR of MDD recurrence in patients who used SED/HYP over 1 DDD in 1 month than those who used SED/HYP less than 1 DDD in 1 month, with the highest-dose users having the highest risk of MDD recurrence (AHR = 7.91; 95% CI = 6.86-9.11).

Conclusions: Patterns and characteristics of sedative-hypnotic use may affect depression recurrence. These findings should be considered by clinicians when combining sedative-hypnotics with antidepressant treatment.

Keywords: Antidepressants; Depression; Sleep; Survival analysis.

PubMed Disclaimer

Similar articles

References

    1. Alloy LB, Olino T, Freed RD, Nusslock R (2016) Role of reward sensitivity and processing in major depressive and bipolar spectrum disorders. Behav Ther 47(5):600–621. https://doi.org/10.1016/j.beth.2016.02.014
    1. Ashton H (2005) The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 18(3):249–255. https://doi.org/10.1097/01.yco.0000165594.60434.84 - DOI - PubMed
    1. Atkin T, Comai S, Gobbi G (2018) Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery. Pharmacol Rev 70(2):197–245. https://doi.org/10.1124/pr.117.014381 - DOI - PubMed
    1. Boden JM, Fergusson DM (2011) Alcohol and depression. Addiction 106(5):906–914. https://doi.org/10.1111/j.1360-0443.2010.03351.x
    1. Brady KT, Sinha R (2005) Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress. Am J Psychiatr 162(8):1483–1493. https://doi.org/10.1176/appi.ajp.162.8.1483

LinkOut - more resources